[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vaping-cessation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vaping-cessation":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,49,84,110,132],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100634522","social-media-support-groups-for-adolescent-vaping-cessation-100634522",false,"NCT07540780","Social Media Support Groups for Adolescent Vaping Cessation","Inclusion Criteria:\n\n1. English literacy\n2. Age between 13-21 years (group participants) or 18+ (coaches, peer mentors)\n3. Indicate they use social media \"most\" (\\>= 4) days per week (group participants)\n4. Have vaped at least once per week in the past 30 days (90 percent of participants) (group participants)\n5. Access to a computer or mobile phone with photo capability to verify abstinence from vaping (group participants)\n6. Indicate they are considering quitting or are interested in quitting with the next 6 months or within the next 30 days (group participants)\n7. Currently reside in California, Minnesota, Oklahoma, or South Carolina\n\nExclusion Criteria:\n\n1. No English literacy\n2. Age under 13 or over 21 (group participants) or under 18 (coaches, peer mentors)\n3. Insufficient social media use (3 or fewer days per week) (group participants)\n4. Have not vaped at least once per week in past 30 days (group participants)\n5. No access to computer or mobile phone with photo capability to verify abstinence from vaping (group participants)\n6. Not considering or interested in quitting vaping in the next 30 days or 6 months (group participants)\n7. Not a resident of California, Minnesota, Oklahoma, or South Carolina",true,"ALL","13 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"NA","The purpose of this study is to pilot test feasibility and acceptability of the Quit the Hit Toolkit, a social media-based nicotine vaping cessation program for adolescents and young adults, adapted for use in community settings.",[26,27,28],"Vaping","Vaping Cessation","Nicotine Dependence",[30,31,32,33,34,35],"single arm","pilot","intervention","vaping","adolescent","young adult","RECRUITING","2026-06-04",{"date":39,"type":40},"2026-06-08","ACTUAL",{"date":42,"type":40},"2026-04-15",{"date":44,"type":20},"2026-08",{"name":46,"class":47},"University of California, San Francisco","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":21,"phases":61,"briefSummary":62,"conditions":63,"keywords":70,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":48},"100608922","parents-helping-parents-for-youth-vaping-cessation-100608922","NCT07207850","Parents Helping Parents for Youth Vaping Cessation","Parents Helping Parents for Youth Vaping Cessation (PhP-VX)","PhP-VX","ADOLESCENT INCLUSION:\n\n* 15-18\n* Report vaping in the previous 30 days\n* English literacy\n\nPARENT INCLUSION:\n\n* Biological, adoptive, stepparents, or adult guardian of adolescent participating\n* Have face-to-face contact with the adolescent at least one day per week during the study period\n* Access to a computer or mobile phone at home\n* Interested in helping adolescent quit e-cigarette\u002Fvape use","15 Years","18 Years",{"count":60,"type":20},200,[23],"The goal of this randomized controlled study is to test if this new intervention works to help adolescents quit vaping. A key feature of the program is the use of peer support for parents, delivered by trained parent coaches. Participants will complete baseline and follow up surveys. Parents in the intervention arm will receive peer support as part of the program.",[64,65,66,67,68,27,69],"Implementation Science","Engagement, Patient","E Cigarette Use","Peer Support","Vaping Teens","Parent Support",[26,71,72,73,74],"Tobacco","vaping cessation","Parent support","adolescent vaping","2026-05-20",{"date":77,"type":40},"2026-05-26",{"date":79,"type":40},"2026-05-18",{"date":81,"type":20},"2027-08-31",{"name":83,"class":47},"University of Nebraska",{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":16,"minAge":58,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":21,"phases":94,"briefSummary":96,"conditions":97,"keywords":98,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":4},"100623091","phase-3-phase-3-trial-evaluating-the-efficacy-and-safety-of-cytisinicline-for-vaping-cessation-in-adults-using-nicotine-containing-e-cigarettes-100623091","NCT07392125","Phase 3 Trial Evaluating the Efficacy and Safety of Cytisinicline for Vaping Cessation in Adults Using Nicotine-Containing E Cigarettes","A Multicenter, Double-blind, Randomized, Placebo-controlled Phase 3 Trial Evaluating the Efficacy and Safety of Cytisinicline for Vaping Cessation in Adults Using Nicotine-Containing E Cigarettes","ORCA-V2","Inclusion Criteria:\n\n* Male or female subjects, age ≥18 years.\n* Test positive for cotinine using a point-of-care Oral Fluid Screening Device (OFD) with positive detection at ≥30 ng\u002FmL cotinine.\n* Current daily nicotine-containing electronic cigarette usage as recorded in a screening diary for at least 7 consecutive days. Willing to bring the e-cigarette or nicotine device used to the clinical site so that the specific product type, flavor, and nicotine level can be documented.\n* Failed at least one previous attempt to stop vaping with or without therapeutic support.\n* Willing to initiate study treatment on the day after randomization and set a quit date within Day 7 and Day 14.\n* Willing to actively participate in the study's vaping cessation behavioral support provided throughout the study.\n* Able to fully understand study requirements, willing to participate, and comply with dosing schedule.\n* Sign the Informed Consent Form.\n\nExclusion Criteria:\n\n* Currently smoking or having smoked within 3 months prior to study randomization, any combustible cigarettes, other combustible tobacco products or non-combustible tobacco products such as heat not burn products or nicotine pouches (ie, dual users).\n* Currently smoking\u002Fvaping cannabis or having smoked or vaped cannabis within 4 weeks (28 days) prior to study randomization or planned use while on study. Other methods of cannabis consumption, eg, edibles, tinctures, capsules, topicals, etc. are allowed.\n* Expired Carbon Monoxide (CO) levels ≥6 ppm, indicating recent combustible tobacco or cannabis smoking.\n* A score of 0-3 on the Penn State e-Cigarette Dependence Index indicating no dependence.\n* More than 1 study subject in same household during the study treatment period.\n* Known hypersensitivity to any of the excipients, previous cytisinicline treatment in a prior clinical study, or any previous use of cytisinicline.\n* Positive urinary drugs of abuse screen determined within 28 days before the first dose of study drug. (Note: Although THC is part of the standard drug screen, it is not necessarily exclusionary. Refer to exclusion criteria #2).\n* Clinically significant abnormal serum chemistry or hematology values, as determined by the investigator, within 28 days of randomization.\n* Clinically significant abnormalities on screening visit 12-lead ECG, as determined by the investigator, after minimum of 5 minutes in supine position within 28 days of randomization.\n* Recent history (within 3 months prior to screening) of acute myocardial infarction, unstable angina, stroke, cerebrovascular incident or hospitalization for congestive heart failure.\n* Current uncontrolled hypertension (systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg).\n* Currently psychotic or having had a psychotic event in the 3 months prior to the screening visit. If any subject becomes psychotic during the study, they must be removed from treatment and\u002For additional study visits.\n* Currently having suicidal ideation or risk for suicide (YES to either question 3, 4 or 5 OR YES to any suicidal behavior question on the C-SSRS with clear suicidal intent or suicide attempt within the last 10 years).\n* Current symptoms of moderate to severe depression (depression score ≥11 using depression questions on the Hospital Anxiety and Depression Scale \\[HADS\\] at screening visit).\n* Renal impairment defined as a creatinine clearance (CrCl) \\\u003C60 mL\u002Fmin at screening visit (estimated with the Cockroft-Gault equation and reported by the central laboratory).\n* Hepatic impairment defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\>2.0 x the upper limit of normal (ULN) at screening visit.\n* Recent history or symptoms (within 4 weeks of randomization) of unstable respiratory disease (eg, pneumonia, product-use associated lung injury or EVALI, etc).\n* Women who are pregnant or breast-feeding.\n* Female subjects of childbearing potential who do not agree to use acceptable methods of birth control during the study. Acceptable methods of birth control include:\n* True abstinence: When this is in line with the preferred and usual lifestyle of the subject. \\[Periodic abstinence (eg, calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception\\].\n* Barrier methods:\n* diaphragm\n* cervical cap\n* contraceptive sponge\n* intrauterine device (IUD)\n* double barrier method (condom with spermicide)\n* Hormonal methods:\n* Oral contraceptives\n* Vaginal ring such as NuvaRing\n* Skin patch such as Xulane\n* Injection such as Depro-Provera\n* Implantable rod such as Nexplanon\n* Intrauterine device (IUD)\n* Participation in a clinical study with an investigational drug or biologic in the 4 weeks prior to study randomization.\n* Use of any smoking cessation medications (bupropion, varenicline, nortriptyline, or any nicotine replacement therapy \\[NRT\\]) in the 4 weeks prior to study randomization or planned use of these or other nicotine replacement medications during the study.\n* Any planned use during the study of combustible cigarettes or other nicotine-containing, non-vaping products (eg, pipe tobacco, cigars, snuff, smokeless tobacco, hookah, ZYN pouches, etc).\n* Any other reason that the investigator views the subject should not participate or would be unable to fulfill the requirements for the study.",{"count":93,"type":20},800,[95],"PHASE3","This will be a multi-center, double-blind, randomized, placebo-controlled, Phase 3 study conducted in male or female adults who are daily nicotine e-cigarette users only.\n\nA total of approximately 800 subjects will be randomly assigned (1:1) to one of two Arms:\n\n* Arm B, 12 weeks cytisinicline + behavior support: N=400 or\n* Arm A, 12 weeks of placebo+ behavior support: N=400) The primary objective is to assess whether subjects randomized to Arm B (3 mg cytisinicline TID for 12 weeks plus behavioral support) have a higher probability of nicotine vaping cessation from Week 9 to Week 12 as compared to subjects randomized to Arm A (placebo TID for 12 weeks plus behavioral support).",[27],[72],"NOT_YET_RECRUITING","2026-01-29",{"date":102,"type":40},"2026-02-06",{"date":104,"type":20},"2026-05-15",{"date":106,"type":20},"2027-09-30",{"name":108,"class":109},"Achieve Life Sciences","INDUSTRY",{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":16,"minAge":58,"maxAge":117,"enrollmentInfo":118,"targetDuration":4,"studyType":21,"phases":120,"briefSummary":121,"conditions":122,"keywords":4,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":4},"100564234","mindful-breaths-mindfulness-for-young-adult-vaping-100564234","NCT06626529","Mindful Breaths: Mindfulness for Young Adult Vaping","Mindful Breaths: A Pilot Randomized Trial on Mindfulness for Young Adult Vaping","Inclusion Criteria:\n\n* Young adults aged 18-29 years old\n* Residing in the United States\n* Able to read and speak English\n* Vape nicotine at least 25 days\u002Fmonth,\n* Interested in cutting down or quitting vaping in the next 30 days (rated at least a 5 on a 10-point scale).\n\nExclusion Criteria:\n\n* Using any nicotine-containing products other than e-cigarettes\n* A current or past Diagnostic and Statistical Manual of Mental Disorders (DSM-5) psychiatric diagnosis of severe mental illness\n* A current DSM diagnosis of substance use disorders other than tobacco use disorder\n* Involved in regular mindful practice\n* Undergoing current smoking\u002Fvaping cessation treatment (counseling and\u002For medication)\n* Taking any medications that may potentially affect nicotine craving, consumption, or mood within the past 30 days.","29 Years",{"count":119,"type":20},120,[23],"The goal of this clinical trial is to evaluate the feasibility, acceptability, and preliminary efficacy of mindfulness-based interventions (MBI) as a vaping cessation intervention in young adults aged 18-29 who vape nicotine at least 25 days per month and are interested in cutting down or quitting. The main questions it aims to answer are:\n\n* Can mindfulness practice reduce nicotine cravings in young adults?\n* Is mindfulness practice an acceptable and feasible intervention for vaping cessation in this population?\n\nResearchers will compare participants in the mindfulness intervention group to a control group that watches a video with calming music and images to see if mindfulness practice has a greater effect on reducing nicotine cravings.\n\nParticipants will:\n\n* Complete a baseline survey and craving cue reactivity assessment.\n* Engage in a 10-minute guided mindfulness meditation (intervention group) or view calming music and images (control group).\n* Rate their cravings and the acceptability, appropriateness, and feasibility of the intervention after the session.",[27],"2025-07-18",{"date":125,"type":40},"2025-07-23",{"date":127,"type":20},"2025-08",{"date":129,"type":20},"2025-12",{"name":131,"class":47},"Tulane University",{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":15,"sex":16,"minAge":140,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":21,"phases":143,"briefSummary":144,"conditions":145,"keywords":146,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":48},"100580038","phase-3-nicotine-patch-plus-nicotine-mouth-spray-versus-nicotine-reduction-for-vaping-cessation-100580038","NCT06832098","Nicotine Patch Plus Nicotine Mouth Spray Versus Nicotine Reduction for Vaping Cessation","The New Zealand Quit Vaping Trial: Combination Nicotine Replacement Therapy Versus Nicotine Reduction.","EQUIT3","Inclusion Criteria:\n\n* Live in New Zealand.\n* Vape nicotine at least weekly (one or more days out of the past seven days).\n* Used to smoke (i.e. they have smoked tobacco regularly but not at all in the past six months) or have never smoked (i.e., they have never been a regular user of smoked tobacco, defined as less than 100 cigarettes in their lifetime).\n* Are aged ≥16 years.\n* Are motivated to quit vaping in the next eight weeks.\n* Are able to provide consent.\n* Have access to the internet via a computer or smart phone.\n* Are a registered patient at a New Zealand medical facility.\n\nExclusion Criteria:\n\n* They have another person in their household currently enrolled in the study.\n* They smoke tobacco currently or were a recent regular user of tobacco.\n* They are enrolled in another vaping cessation programme\u002Ftrial.\n* They self-report having had a serious cardiovascular event, or hospitalisation for a cardiovascular complaint, in the previous four weeks (e.g. stroke, myocardial infarction, unstable angina, cardiac arrhythmia, coronary artery bypass graft and angioplasty).\n* They self-report uncontrolled hypertension.\n* They have a strong preference to use\u002Fnot use NRT or nicotine tapering.\n* They are current users of smoking cessation pharmacotherapy (e.g. NRT, varenicline, cytisine, nortriptyline \\[including if it is used for a different indication\\], and amitriptyline \\[as it converts to nortriptyline\\].\n* They are currently enrolled in another vaping cessation programme\u002Ftrial.","16 Years",{"count":142,"type":20},774,[95],"This research focuses on maximizing the chances of successfully quitting vaping. A large, pragmatic community-based clinical trial is planned in New Zealand to build on existing evidence from previous vaping and smoking cessation research undertaken by the study team. The effectiveness of combination nicotine replacement therapy (NRT) compared to nicotine tapering on vaping abstinence has not yet been investigated, but both provide an opportunity to increase success with vaping cessation, especially when combined with written behavioural support to further boost quit rates.\n\nThe planned trial will test whether using combination NRT will help more New Zealanders to quit vaping long-term, compared with a vape nicotine tapering plan. Participants in both groups will also receive written vaping cessation behavioural support.",[27],[147,148,149,150,151,152,153,154],"Nicotine tapering","Pragmatic","Effectiveness","Vaping cessation","Nicotine Replacement Therapy","e-cigarette","nicotine mouth spray","nicotine patch","2025-03-29",{"date":157,"type":40},"2025-04-03",{"date":159,"type":40},"2025-03-25",{"date":161,"type":20},"2027-04-30",{"name":163,"class":47},"University of Auckland, New Zealand"]